PDF
File
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, 21 June 2024 - ExpreS[2]ion Biotech Holding AB's affiliate ExpreS[2]ion Biotechnologies ApS ("ExpreS2ion") announces the new publication in The Lancet of a scientific paper titled "Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial". The article is based on a clinical study conducted by researchers at the University of Oxford.
Chief Scientific Officer Farshad Guirakhoo comments:
"These are the first data on the RH5.1/Matrix-M blood-stage malaria vaccine's safety and immunogenicity in Tanzania published in the Lancet. These findings indicate the highest levels of functional antibody responses recorded to date in the malaria vaccine target population: young African children. The results are promising and support the ongoing Phase IIb efficacy trial of RH5.1/Matrix-M in Burkina Faso."
The article can be reached via this link: https://doi.org/10.1016/S1473-3099(24)00312-8.
About University of Oxford's malaria vaccine programs employing the ExpreS2™ system
Since the first research license agreement in 2012, ExpreS2ion has been supporting the University of Oxford's malaria vaccine research groups, led by Prof. Simon J. Draper, Professor of Vaccinology and Translational Medicine, Department of Biochemistry, and Associate Professor Sumi Biswas, Transmission-blocking Malaria Group, The Jenner Institute. Four clinical-stage malaria vaccine projects have emerged from these efforts, RH5.1, R78C, RH5.2-VLP, and Pfs48/45, all relying on ExpreS2ion's unique ExpreS2™ technology for the antigen manufacturing. This technology has been the only system capable of producing sufficient amounts of the active ingredient necessary for on-going development. To date, these four clinical-stage malaria vaccine projects are undergoing a total of seven clinical studies, detailed as follows:
[]
Trial Phase Sites Vaccines Trial status Year
abbreviation in trial started
VAC089 Ia Oxford, UK RH5.1[1] Vaccinations on 2023
-going
R78C
VAC086 Ib MRC unit, The RH5.2 Vaccinations on 2023
Gambia -VLP -going
R21-VLP
VAC091 IIb IRSS CRUNBurkina RH5.1 Vaccinations on 2023
Faso -going
RH5.2
-VLP
BIO-001 I/IIa Oxford, UK RH5.1 Screening 2023
&vaccinations on
RH5.2 -going
-VLP
BIO-002 I Sheffield, UK RH5.1 Vaccinations on 2023
-going
BIO-003 I IHI RH5.1 In set-up N/A
BagamoyoTanzania
R78C
VAC-085 I Oxford, UK Pfs48/45 Vaccinations on 2023
-going
The four malaria vaccine research programs, that ExpreS2ion has a part in by virtue of basing the manufacturing on the Company's proprietary protein expression system made in Drosophila S2 insect cells, are all in the current clinical study set-up financed by grants applied for and awarded to the University of Oxford and/or its collaborating partners. All the vaccines apply the adjuvant Matrix-M™ from Novavax.
[1 ]Silk et al, Lancet (2024): Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Certified Adviser
Svensk Kapitalmarknadsgranskning AB